Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$251.1M
31M shares
52-week range
$3.22 – $8.55
90% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
ADRC
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
www.avitamedical.comNo one on the platform currently holds RCEL.
No tracked institution reports a position in RCEL as of their last filing.
No one on the platform has traded RCEL yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$RCEL Sold 95% of my shares today with 80% profit. I'll be back if we see 6s again. I still think $16 EOY is possible.
View on StockTwits ↗$RCEL Can't find replay of the investor talk yet. Missed it live.
View on StockTwits ↗$RCEL My Canaccord takeaways: - expecting ongoing sequential growth - dramatic reduction in use of cash - holding G&A - simplified reimbursement Jan 1, 2027 - only 25 locations using all three products - 20 day improvement using Cohealyx - Positioned to grow year plus without adding sales reps
View on StockTwits ↗$RCEL Great investor talk. Lots of room, great ecosystem.
View on StockTwits ↗$RCEL Tight Cash Runway & Capital Needs: AVITA carries a relatively short cash runway based on its free cash flow burn. If revenues ramp up slower than projected, the company may need to raise additional capital. Risk of Shareholder Dilution: AVITA has historically used equity offerings to fund operations. Future secondary stock offerings could dilute existing shareholders.
View on StockTwits ↗$RCEL Extremely overvalued!! It is going back down to $5.00’s range imo. After a long Dd Ongoing Unprofitability & Negative Cash Flow: The company is not currently profitable, sporting a negative profit margin and ongoing net losses. Analyst expectations generally target cash flow breakeven around late 2026 or 2027/2028, leaving the stock vulnerable to earnings delays or cost overruns.
View on StockTwits ↗$RCEL a micro cap at 3x revenue and 2x forward at current price. This is rocketing now
View on StockTwits ↗$RCEL https://www.sec.gov/ix?doc=/Archives/edgar/data/0001762303/000119312526344787/rcel-20260805.htm
View on StockTwits ↗$RCEL if you are wondering why this popped, it is because the business has just made the critical turnaround
View on StockTwits ↗$RCEL earnings was not this great , this needs to drop below 6....
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $83M | +15.8% | $-1.05 | $-1.20–$-0.95 | — | 3 |
| 2027 | $100M | +20.9% | $-0.54 | $-0.62–$-0.49 | — | 3 |
| 2028 | $123M | +22.6% | $-0.05 | $-0.13–$0.04 | — | 3 |
| 2029 | $411M | +235.3% | $2.76 | $2.50–$3.16 | 2.9× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| RCELAvita Medical Inc. | $8.01 | -1.35% | $199M | — |
| APYXApyx Medical Corporation | $3.04 | +1.67% | $128M | — |
| FONRFonar Corp. | $19.09 | +0.00% | $118M | — |
| HYPRHyperfine, Inc. | $0.89 | -0.81% | $75M | — |
| LUCDLucid Diagnostics Inc. | $0.96 | -1.98% | $184M | — |
| NSPRInspireMD, Inc. | $0.84 | -2.31% | $39M | — |
Source: Financial Modeling Prep · peers by sector/industry
| OVIDOvid Therapeutics Inc. | $2.80 | +6.87% | $523M | — |